Compound News and Research

RSS

Vytacera Pharma to develop Sulfanegen for treatment of cyanide poisoning

Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.

10 Feb 2012

FDA panel votes against Amgen’s Xgeva in prostate cancer

An FDA panel of oncologists has voted against a new use for Amgen's Xgeva in prostate cancer on Wednesday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients. Xgeva is already approved to prevent fractures in cancerous bones, and for osteoporosis, in a different formulation called Prolia.

9 Feb 2012

Scripps Research, Brooks partner to develop and commercialize Plate Auditor

Brooks Life Science Systems, a division of Brooks Automation, Inc., a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets, today announced the initiation of a technology development and commercialization partnership with The Scripps Research Institute.

9 Feb 2012

Scientists study a botanical formula that kills aggressive prostate cancer tumors

Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology.

9 Feb 2012

Hitachi Aloka Medical releases F37 digital diagnostic ultrasound system

Hitachi Aloka Medical, Ltd. announced the release of a new digital diagnostic ultrasound system, F37. F37 was developed focusing on contributing to primary care, such as in clinics and examination institutions.

8 Feb 2012

FGF21 hormone causes significant and rapid bone loss in mice

An endocrine hormone used in clinical trials as an anti-obesity and anti-diabetes drug causes significant and rapid bone loss in mice, raising concerns about its safe use, UT Southwestern Medical Center researchers have shown.

7 Feb 2012

Forum for Collaborative HIV Research suggests new approach for conducting Phase 3 HIV clinical trials

As the war on HIV/AIDS begins its fourth decade, medical researchers, pharmaceutical manufacturers, patient advocates and government regulators face a new and unexpected scientific challenge: how to demonstrate the safety and efficacy of promising new antiretroviral drugs when the two traditional study designs – the superiority trial and the non-inferiority trial – are no longer useful in showing improvements in both "treatment experienced" patients and those who have never received drug therapy (treatment-naive patients).

7 Feb 2012

Novel stem-cell technique to enhance bone growth

A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones.

7 Feb 2012

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

6 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Colchicine, another weapon against cancer

Finding a drug that targets only the diseased cells in our body and is otherwise harmless to healthy tissue is a goal for cancer researchers. It's driven the work of Professor Laurence Patterson, Director of the Institute of Cancer Therapeutics at the University of Bradford, and his team of researchers.

2 Feb 2012

Prestige acquires 15 brands from GSK

Prestige Brands Holdings, Inc. today announced that it has completed its previously announced purchase of fifteen of the seventeen brands it agreed to acquire from GlaxoSmithKline (GSK).

1 Feb 2012

OPN-305 may improve survival outcomes for kidney transplant patients

New research published online in the FASEB Journal details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs.

1 Feb 2012

Potential way to block second wave of death from pneumonia treatment

An international research team may have found a way to block a second wave of death that can result from pneumonia treatment.

1 Feb 2012

Specific gene mutation triggers development of NAFLD

A team of scientists from the University of Utah and the University of California at San Francisco has discovered that the mutation of a gene encoding a ketone body transporter triggers accumulation of fat and other lipids in the livers of zebrafish.

1 Feb 2012

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Clorox launches new H2O2 cleaner disinfectant wipes and spray

Clorox Professional Products Company, a division of The Clorox Company announced today the introduction of Clorox Healthcare(TM) Hydrogen Peroxide Cleaner Disinfectant Wipes and Spray, a new line of ready-to-use, one-step cleaner disinfectants engineered with a patented activated hydrogen peroxide (H2O2) formula.

31 Jan 2012

HSP40/70 linked to hepatitis C infection

Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks viral replication, which can lead to liver cancer and cirrhosis.

31 Jan 2012

DWH signs collaboration agreement with CPDD

Developing World Health (DWH), a leading medical charity based in Stirlingshire, Scotland and committed to developing effective treatments for neglected tropical diseases, has signed a collaboration agreement with the internationally respected Consortium for Parasitic Drug Development (CPDD), based at The University of North Carolina at Chapel Hill.

27 Jan 2012